STOCK TITAN

Keros Therapeutics director plans 575-share sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) director Anne Prener reported a planned sale of 575 common shares, with an approximate sale date of November 17, 2026, and an aggregate market value of $5,761.50. The plan adoption or instruction date associated with Rule 10b5-1 reliance is August 6, 2026. Anne Prener also reported selling 574 shares on November 12, 2026, for gross proceeds of $5,619.46.

Planned sale 575 common shares Approximate sale date November 17, 2026
Aggregate market value $5,761.50 Planned sale of 575 common shares
Shares outstanding 19,624,374 shares Reported in the securities information
Prior reported sale 574 common shares Sold November 12, 2026
Gross proceeds $5,619.46 Prior reported sale on November 12, 2026
Shares acquired through RSU vesting 575 common shares Acquired November 15, 2026
Rule 10b5-1 plan adoption or instruction date August 6, 2026 Date reported for Rule 10b5-1 reliance
RSU Vesting financial
"Nature of Acquisition Transaction: RSU Vesting"
RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.
Rule 10b5-1 regulatory
"If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KROS shares did Anne Prener plan to sell?

Anne Prener reported a planned sale of 575 Keros Therapeutics common shares, with an approximate sale date of November 17, 2026, and an aggregate market value of $5,761.50.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading